Gilead Sciences Wins FDA Approval for First HDV Treatment Hepcludex

Gilead Sciences (NASDAQ: GILD) received FDA approval on May 22, 2026, for Hepcludex injection to treat chronic hepatitis delta virus infection in adults. The company also completed the acquisition of Tubulis GmbH for $3.15 billion upfront with potential additional payments.

By Jeff Lewis Fri, May 29, 2026 at 9:04 AM GMT+3 2 min read · Yahoo Finance · May 29, 2026, 06:04 UTC

Gilead Sciences Wins FDA Approval for First HDV Treatment Hepcludex

Tickers: $GILD

Topics: biotech drug approval pharmaceuticals

Read the full article at Yahoo Finance

More World news

UBS Upgrades Rivian to Buy Rating Amid R2 Potential Motley Fool · November 12, 2026, 16:45 UTC
Stifel Downgrades EVgo to Hold Amid Weakening Growth Outlook Seeking Alpha · November 12, 2026, 16:41 UTC
Rowan Digital Infrastructure Secures Over $1.5 Billion in New Financing Seeking Alpha · November 12, 2026, 16:42 UTC
CAE Reports Q2 2027 Results with Increased EPS Guidance and Strong Defense Growth Motley Fool · November 12, 2026, 16:39 UTC
Alvotech Reports Q3 2026 Financial Results Amid Manufacturing Recovery Motley Fool · November 12, 2026, 16:39 UTC
Jacobs Solutions Declares Quarterly Dividend of $0.36 Per Share Seeking Alpha · November 12, 2026, 16:39 UTC
SOLV Energy Raises Revenue Guidance Following Record Q3 Project Execution Seeking Alpha · November 12, 2026, 16:40 UTC
LiveWorld Reports Q3 Revenue of $2.98 Million and GAAP EPS of -$0.01 Seeking Alpha · November 12, 2026, 16:37 UTC
Jensen Huang Resigns as Nvidia CEO Amid Allegations of Chinese Espionage The Verge · November 12, 2026, 16:30 UTC
Rising New Vehicle Monthly Payments Pose Affordability Risks for Ford and General Motors Motley Fool · November 12, 2026, 16:33 UTC